Press release
Castration-Resistant Prostate Cancer Market Size, Share and Growth Report, 2034
Castration-Resistant Prostate Cancer Market
The Castration-Resistant Prostate Cancer (CRPC) Market is poised for steady expansion, driven by breakthroughs in androgen receptor-targeted agents, immuno-oncology, and radioligand therapy. CRPC, a form of prostate cancer that progresses despite androgen deprivation therapy (ADT), remains one of the most challenging stages to treat. The increasing availability of precision diagnostics, biomarker-guided treatment selection, and combination regimens is transforming patient outcomes and fueling market growth.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/70813
Market Overview - Key Highlights
• Market Size 2024: USD 10.95 billion
• Forecasted Market Size 2034: USD 19.25 billion
• CAGR (2024-2034): ~5.8%
• Key Growth Drivers: Increasing adoption of novel hormonal agents, expansion of radiopharmaceuticals, and rise in global prostate cancer prevalence.
• Challenges: High treatment costs, drug resistance over time, and unequal access to advanced therapies in emerging markets.
• Leading Players: Johnson & Johnson (Janssen Biotech), Pfizer Inc., Astellas Pharma Inc., Bayer AG, Novartis AG, AstraZeneca plc, Bristol Myers Squibb.
Market Segmentation
By Therapy Type
• Next-Generation Hormonal Agents (Enzalutamide, Abiraterone, Apalutamide, Darolutamide)
• Chemotherapy (Docetaxel, Cabazitaxel)
• Radiopharmaceuticals (Radium-223, PSMA-targeted agents)
• Immunotherapy (Sipuleucel-T, Checkpoint Inhibitors)
• Supportive Care
By Route of Administration
• Oral
• Injectable
By End-User
• Hospitals
• Specialty Cancer Centers
• Ambulatory Care Centers
Segmentation Summary:
Next-generation hormonal agents lead the CRPC market due to their proven survival benefits and established role in treatment guidelines. Radiopharmaceuticals, especially PSMA-targeted therapies, are emerging as high-growth segments.
Get Your Exclusive Offer with up to 10% Discount:
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70813
Regional Analysis
• North America:
Dominates due to high adoption of advanced therapeutics, strong oncology infrastructure, and favorable reimbursement systems.
• Europe:
Significant share driven by structured cancer care pathways, high patient awareness, and robust clinical trial activity.
• Asia-Pacific:
Fastest-growing region due to increasing prostate cancer incidence, improving diagnostic capabilities, and expanded access to novel agents.
• Middle East & Africa:
Moderate growth with gradual integration of advanced treatments in urban centers.
• Latin America:
Steady growth led by Brazil, Mexico, and Argentina, with rising access to hormonal therapies and chemotherapy.
Regional Summary:
While North America leads in market share, Asia-Pacific is expected to post the highest CAGR over the forecast period due to healthcare modernization and growing clinical trial participation.
Market Dynamics
Key Growth Drivers:
• Expanding role of PSMA-targeted radioligand therapy.
• Rising adoption of combination regimens in earlier CRPC stages.
• Increasing use of liquid biopsy and genomic profiling for treatment selection.
Key Challenges:
• Resistance development to hormonal agents.
• High therapy costs limiting adoption in low-income countries.
• Managing treatment-related side effects in elderly populations.
Latest Trends:
• Integration of AI and predictive analytics in treatment decision-making.
• Growth of biomarker-driven clinical trials.
• Development of next-generation androgen receptor inhibitors with better safety profiles.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/70813/castration-resistant-prostate-cancer-market
Competitive Landscape
Major Players:
1. Johnson & Johnson (Janssen Biotech)
2. Pfizer Inc.
3. Astellas Pharma Inc.
4. Bayer AG
5. Novartis AG
6. AstraZeneca plc
7. Bristol Myers Squibb
8. Ipsen Pharma
9. Merck & Co., Inc.
10. Sanofi S.A.
Competition Summary:
The CRPC market is innovation-intensive, with leading companies investing in novel drug development, radioligand technology, and personalized medicine approaches to improve patient survival and quality of life.
Conclusion
The Castration-Resistant Prostate Cancer Market is expected to grow steadily through 2034, driven by therapeutic innovations, biomarker-based treatment strategies, and expanding global access. Companies that focus on combination therapies, affordability, and emerging market penetration will be best positioned to lead in this evolving landscape.
This report is also available in the following languages : Japanese (去勢抵抗性前立腺がん市場), Korean (거세 저항성 전립선암 시장), Chinese (去势抵抗性前列腺癌市场), French (Marché du cancer de la prostate résistant à la castration), German (Markt für kastrationsresistenten Prostatakrebs), and Italian (Mercato del cancro alla prostata resistente alla castrazione), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/70813
Our More Report:
Cloud Logistics
https://exactitudeconsultancy.com/reports/65812/cloud-logistics-market
Cloud OSS BSS
https://exactitudeconsultancy.com/reports/65814/cloud-oss-bss-market
Distributed Cloud
https://exactitudeconsultancy.com/reports/65816/distributed-cloud-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Castration-Resistant Prostate Cancer Market Size, Share and Growth Report, 2034 here
News-ID: 4141951 • Views: …
More Releases from Exactitiude Consultancy
Non-Muscle Invasive Bladder Cancer Market Industry Analysis by Size, Share, Grow …
Introduction
The Non-Muscle Invasive Bladder Cancer (NMIBC) market is poised for significant growth as advancements in intravesical therapies, immuno-oncology drugs, and molecular diagnostics improve patient outcomes. NMIBC, which accounts for about 70-75% of all newly diagnosed bladder cancer cases, is characterized by high recurrence rates but relatively low mortality compared to muscle-invasive forms. The rising global prevalence, particularly among aging populations, is prompting greater investment in early diagnosis, novel drug delivery…
NK Cell Therapy Market Size And Global Industry Forecast 2034
NK Cell Therapy Market Outlook 2024-2034: Immuno-Oncology Innovation and Off-the-Shelf Therapies Set the Stage for Rapid Growth
Introduction
The Natural Killer (NK) Cell Therapy market is one of the most dynamic segments in immuno-oncology, driven by breakthroughs in cell engineering, off-the-shelf allogeneic therapies, and combination regimens with checkpoint inhibitors. NK cells, part of the innate immune system, have demonstrated strong potential in targeting and destroying cancer cells without prior sensitization, making them…
Neuroendocrine Prostate Cancer Market Size, Share and Growth Report, 2034
Introduction
The Neuroendocrine Prostate Cancer (NEPC) market is emerging as a key focus area in oncology due to its aggressive nature, poor prognosis, and increasing recognition as a distinct clinical entity. NEPC can develop de novo or as a treatment-emergent form of advanced prostate cancer following androgen deprivation therapy (ADT) resistance. While rare, NEPC is challenging to treat, requiring a combination of chemotherapy, targeted agents, and investigational therapies. Rising awareness, advancements…
Metastatic Colorectal Cancer Market Size And Global Industry Forecast 2034
Introduction
The Metastatic Colorectal Cancer (mCRC) market is entering a transformative phase as precision medicine, biomarker-driven treatment strategies, and immunotherapy reshape patient care. Increasing adoption of EGFR inhibitors, VEGF inhibitors, immune checkpoint inhibitors, and combination regimens is improving survival rates, while advancements in molecular diagnostics are enabling more tailored treatment approaches. Over the next decade, continuous R&D efforts and expanded access to innovative therapies are expected to drive market growth.
Download Full…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
